Eisai expands into Brazil

Friday, April 8, 2011 10:24 AM

Eisai, based in Japan, is moving into Latin America and is opening a subsidiary in Brazil, according to Pharma Times.

Eisai Brazil will be based in Sao Paulo, the country’s largest city, and will first establish "an initial infrastructure to support its operations debut" into that market. The company will focus on neurology, oncology and critical care.

Hajime Shimizu, president of new markets and the Association of Southeast Asian Nations (ASEAN) for Eisai, said the establishment of the unit "marks our entry into Latin America.” He added that the expansion "will enable us to introduce many of Eisai’s first-in-class products to people living in Brazil."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs